News

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.

Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.

OPKO Health Inc (OPK) reports significant revenue growth in pharmaceuticals and a notable reduction in net loss, despite challenges in diagnostics.

Inspectors issue stop-work order at planned 32-story apartment tower in Manhattan, carrying out safety sweeps after former Pfizer headquarters building buckled.

(Bloomberg) -- Investors will soon have another way to bet on the hottest stocks from Nvidia Corp. to SpaceX, without trading a single share.Most Read from BloombergDeepSeek Said to Tell Backers of Funding Pause After Viral PostsSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysTrump Seethes as Iran War Spirals Anew With No End in SightHouthis Claim Saudi Attack as US Ends Run of Iran StrikesRetina Chip Designed to Restore Sight to Go on Sale in EuropeCME Group Inc. will launch single

(Bloomberg) -- Investors will soon have another way to bet on the hottest stocks from Nvidia Corp. to SpaceX, without trading a single share.Most Read from BloombergDeepSeek Said to Tell Backers of Funding Pause After Viral PostsSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysTrump Seethes as Iran War Spirals Anew With No End in SightHouthis Claim Saudi Attack as US Ends Run of Iran StrikesRetina Chip Designed to Restore Sight to Go on Sale in EuropeCME Group Inc. will launch single

BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.

(Bloomberg) -- President Donald Trump’s threat of 100% tariffs against generic medicines is a major expansion of a strategy he’s been using against the pharmaceutical industry since his second term began. Most Read from BloombergTrump’s 100% Generic Drug Duty Threatens US Low-Cost SupplyApple to Launch ‘Upgrade’ Device Leasing Program With Klarna to Spur SalesTrump Extends Pardons to Companies, Echoing a 17th Century KingSpaceX Set to Unlock $116 Billion in Shares After IPO Restrictions LiftKrem

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.

Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its profit.

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

Several Midtown blocks were shut down earlier this week after structural problems put the high-rise building at risk of partial collapse.

AstraZeneca and Ionis Pharmaceuticals shares are down roughly 8% and 20%, respectively, after the drugmakers said their heart therapy Wainua failed in a late-stage trial. The companies pointed to a smaller group of patients in the trial to show some potential for the drug: Patients who weren’t already taking either Pfizer or BridgeBio’s drug for this condition saw a relative risk reduction in major heart problems or deaths.

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...

The former Pfizer headquarters in Midtown has continued to move since emergency responders arrived, officials said Tuesday.

A high-rise building in Manhattan was at risk of collapse after columns buckled and floors sagged, officials said Tuesday, prompting an emergency response during the rush-hour commute. Fire officials said they received a report that bricks were falling from the 38-story building, in the city’s midtown district just before 8 a.m. Officials determined that two columns had buckled on the building’s 21st and 22nd floors and that several floors near the columns were sagging. No injuries were reported, fire officials said.

Could this be the secret to Pfizer's rebound strategy?

(Bloomberg) -- President Donald Trump made more than 21,000 securities trades in his first year back in office, often in intense bursts tied to market events he created.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileMeta Is Planning a Cloud Business to Sell AI Computing PowerGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileKrafton Agrees to Pay ‘Subnautica 2’ Bonuses as Developer’s CEO

Nike's (NKE) fiscal fourth-quarter revenue slipped year-over-year, while the sportswear company's ea

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a

(Updates with Pfizer's response in the last two paragraphs.) Pfizer (PFE) has been dismissed as a

Nike announced a CFO transition and said fourth-quarter results remain on track, excluding a one-time tariff refund benefit.

David Denton’s appointment, effective Aug. 17, comes as the company struggles to execute its turnaround.

The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.

Global Healthcare Opportunities and CBC Group discussed launching a new global fund after their merger, the firms’ heads said, as the healthcare investors move to tap into Asia’s rise as an innovation hub.